362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1818646224299884544 |
|---|---|
| author | Emmett Schmidt Jonathan Thompson Michael Chisamore James Spicer Åslaug Helland Edurne Arriola Manuel Dómine Gomez Jose Manuel Trigo Perez Ana Laura Ortega Granados Noelly Madeleine Austin Rayford Katherine Lorens Abdul Siddiqui Hani Gabra Jaya Nautiyal David Micklem James Lorens |
| author_facet | Emmett Schmidt Jonathan Thompson Michael Chisamore James Spicer Åslaug Helland Edurne Arriola Manuel Dómine Gomez Jose Manuel Trigo Perez Ana Laura Ortega Granados Noelly Madeleine Austin Rayford Katherine Lorens Abdul Siddiqui Hani Gabra Jaya Nautiyal David Micklem James Lorens |
| author_sort | Emmett Schmidt |
| collection | DOAJ |
| first_indexed | 2024-12-17T00:43:14Z |
| format | Article |
| id | doaj.art-ae2b9c922e2e4cff96ff5a8879f3632b |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-17T00:43:14Z |
| publishDate | 2020-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-ae2b9c922e2e4cff96ff5a8879f3632b2022-12-21T22:09:58ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0362362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysisEmmett Schmidt0Jonathan Thompson1Michael Chisamore2James Spicer3Åslaug Helland4Edurne Arriola5Manuel Dómine Gomez6Jose Manuel Trigo Perez7Ana Laura Ortega Granados8Noelly Madeleine9Austin Rayford10Katherine Lorens11Abdul Siddiqui12Hani Gabra13Jaya Nautiyal14David Micklem15James Lorens16Aff145 grid.417993.10000000122600793Merck & Co., Inc. Kenilworth NJ USA Aff7 0000 0001 2111 8460grid.30760.32Medical College of Wisconsin 8701 W Watertown Plank Rd 53226 Milwaukee WI USA 2Merch and Co., Inc., Rahway, NJ, USA1King’s College London, Guy’s Hospital, London, UK2Oslo University Hospital, Oslo, Norway4Hospital del Mar, Barcelona, Spain5Hospital Universitario Fundación Jiménez, Madrid, Spain6Hospital Virgen de la Victoria, Málaga, Spain9Complejo Hospitalario de Jaén, Jaén, Spain12BerGenBio ASA, Bergen, Norway12BerGenBio ASA, Bergen, Norway12BerGenBio ASA, Bergen, Norway12BerGenBio ASA, Bergen, Norway12BerGenBio ASA, Bergen, Norway12BerGenBio ASA, Bergen, Norway12BerGenBio ASA, Bergen, Norway12BerGenBio ASA, Bergen, Norway |
| spellingShingle | Emmett Schmidt Jonathan Thompson Michael Chisamore James Spicer Åslaug Helland Edurne Arriola Manuel Dómine Gomez Jose Manuel Trigo Perez Ana Laura Ortega Granados Noelly Madeleine Austin Rayford Katherine Lorens Abdul Siddiqui Hani Gabra Jaya Nautiyal David Micklem James Lorens 362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis Journal for ImmunoTherapy of Cancer |
| title | 362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis |
| title_full | 362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis |
| title_fullStr | 362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis |
| title_full_unstemmed | 362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis |
| title_short | 362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis |
| title_sort | 362 a phii study of bemcentinib a first in class selective axl kinase inhibitor in combination with pembrolizumab in pts with previously treated advanced nsclc updated clinical translational analysis |
| work_keys_str_mv | AT emmettschmidt 362aphiistudyofbemcentinibafirstinclassselectiveaxlkinaseinhibitorincombinationwithpembrolizumabinptswithpreviouslytreatedadvancednsclcupdatedclinicaltranslationalanalysis AT jonathanthompson 362aphiistudyofbemcentinibafirstinclassselectiveaxlkinaseinhibitorincombinationwithpembrolizumabinptswithpreviouslytreatedadvancednsclcupdatedclinicaltranslationalanalysis AT michaelchisamore 362aphiistudyofbemcentinibafirstinclassselectiveaxlkinaseinhibitorincombinationwithpembrolizumabinptswithpreviouslytreatedadvancednsclcupdatedclinicaltranslationalanalysis AT jamesspicer 362aphiistudyofbemcentinibafirstinclassselectiveaxlkinaseinhibitorincombinationwithpembrolizumabinptswithpreviouslytreatedadvancednsclcupdatedclinicaltranslationalanalysis AT aslaughelland 362aphiistudyofbemcentinibafirstinclassselectiveaxlkinaseinhibitorincombinationwithpembrolizumabinptswithpreviouslytreatedadvancednsclcupdatedclinicaltranslationalanalysis AT edurnearriola 362aphiistudyofbemcentinibafirstinclassselectiveaxlkinaseinhibitorincombinationwithpembrolizumabinptswithpreviouslytreatedadvancednsclcupdatedclinicaltranslationalanalysis AT manueldominegomez 362aphiistudyofbemcentinibafirstinclassselectiveaxlkinaseinhibitorincombinationwithpembrolizumabinptswithpreviouslytreatedadvancednsclcupdatedclinicaltranslationalanalysis AT josemanueltrigoperez 362aphiistudyofbemcentinibafirstinclassselectiveaxlkinaseinhibitorincombinationwithpembrolizumabinptswithpreviouslytreatedadvancednsclcupdatedclinicaltranslationalanalysis AT analauraortegagranados 362aphiistudyofbemcentinibafirstinclassselectiveaxlkinaseinhibitorincombinationwithpembrolizumabinptswithpreviouslytreatedadvancednsclcupdatedclinicaltranslationalanalysis AT noellymadeleine 362aphiistudyofbemcentinibafirstinclassselectiveaxlkinaseinhibitorincombinationwithpembrolizumabinptswithpreviouslytreatedadvancednsclcupdatedclinicaltranslationalanalysis AT austinrayford 362aphiistudyofbemcentinibafirstinclassselectiveaxlkinaseinhibitorincombinationwithpembrolizumabinptswithpreviouslytreatedadvancednsclcupdatedclinicaltranslationalanalysis AT katherinelorens 362aphiistudyofbemcentinibafirstinclassselectiveaxlkinaseinhibitorincombinationwithpembrolizumabinptswithpreviouslytreatedadvancednsclcupdatedclinicaltranslationalanalysis AT abdulsiddiqui 362aphiistudyofbemcentinibafirstinclassselectiveaxlkinaseinhibitorincombinationwithpembrolizumabinptswithpreviouslytreatedadvancednsclcupdatedclinicaltranslationalanalysis AT hanigabra 362aphiistudyofbemcentinibafirstinclassselectiveaxlkinaseinhibitorincombinationwithpembrolizumabinptswithpreviouslytreatedadvancednsclcupdatedclinicaltranslationalanalysis AT jayanautiyal 362aphiistudyofbemcentinibafirstinclassselectiveaxlkinaseinhibitorincombinationwithpembrolizumabinptswithpreviouslytreatedadvancednsclcupdatedclinicaltranslationalanalysis AT davidmicklem 362aphiistudyofbemcentinibafirstinclassselectiveaxlkinaseinhibitorincombinationwithpembrolizumabinptswithpreviouslytreatedadvancednsclcupdatedclinicaltranslationalanalysis AT jameslorens 362aphiistudyofbemcentinibafirstinclassselectiveaxlkinaseinhibitorincombinationwithpembrolizumabinptswithpreviouslytreatedadvancednsclcupdatedclinicaltranslationalanalysis |